IM Cannabis (IMCC) Capital Expenditures (2020 - 2026)

IM Cannabis (IMCC) posted quarterly Capital Expenditures of -$3646.0 for Q1 2026, down 124.21% quarter-over-quarter from $15058.8 in Q4 2025.

IM Cannabis (IMCC) Capital Expenditures (2020 - 2026) Analysis & Trends

IM Cannabis' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$3646.0 for Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to -$3646.0; the TTM figure through Mar 2026 stood at $210375.7 (changed N/A YoY), while the FY2025 annual figure was $9322.1, down 91.82% from the prior year.
Capital Expenditures for Q1 2026 stood at -$3646.0, down from $15058.8 in the prior quarter.
The five-year high for Capital Expenditures was $1.9 million in Q3 2022, with the low at -$2.2 million in Q4 2022.
The 5-year median for Capital Expenditures is -$20101.5 (2024), against an average of -$42157.1.
The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 296.8% in 2022, then jumped 138.35% in 2023.
IM Cannabis' Capital Expenditures stood at -$2.2 million in 2022, then surged by 138.35% to $832963.3 in 2023, then slumped by 75.76% to $201869.5 in 2024, then slumped by 92.54% to $15058.8 in 2025, then slumped by 124.21% to -$3646.0 in 2026.
Business Quant data shows IMCC's Capital Expenditures at -$3646.0 in Q1 2026, $15058.8 in Q4 2025, and -$2906.5 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	104.00 Mn
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	117.00 Mn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-337.60 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	108.00 Mn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	52.80 Mn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	7.80 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	33.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	IM Cannabis	549,631.99	-619,338.18	1.09 Mn	7,952.18

Download Data